跳至主要内容
临床试验/CTRI/2024/06/069352
CTRI/2024/06/069352尚未招募Unknown

Role of serum Beta Hydroxy Butyrate levels in Doxorubicin and Cyclophosphamide induced neutropenia in breast cancer patients: A Pilot study - NI

DrNPKTeja Self0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • All patients who have histopathologically confirmed breast malignancy and
  • Fit to receive Doxorubicin and Cyclophosphamide chemotherapy
  • Chemotherapy naive
  • Age above 18 years
  • Participants with
  • a.Haemoglobin above 8gm/dl,
  • b.Platelet count above 1,00,000/mm3
  • c.Absolute neutrophil count above 1500/ mm3
  • Patients with Left Ventricular Ejection Fraction more than 50%.
  • Participants with ECOG (Eastern Co-operative Oncology Group) performance status of 0-2.

排除标准

  • Not willing to provide informed consent
  • Participants with history of, use of drugs causing bone marrow toxicity like, Lamotrigine, Dapsone, Quinidine,Quinine, Propylthiouracil, Clozapine, Vancomycin in the past 2 months.
  • Patients with Chronic Kidney Disease with Creatinine clearance lesser than 30ml/min
  • Patients with Chronic hepatic disorders with Serum total Bilirubin greater than 5mg/dl and Transaminases (ALT & AST more than 5 times normal limit
  • Patients with refractory anaemia and with history of blood transfusions
  • Patients with Uncontrolled Diabetes Mellitus with HbA1c greater than or equal to 8% .
  • Diabetic patients receiving Insulin.
  • Patients who are on keto diet.
  • Participants with history of alcohol intake in the past 7 days.
  • Patients with known hypersensitivity to Doxorubicin or Cyclophosphamide.

研究者

发起方
DrNPKTeja Self

相似试验

A preliminary study investigating how a blood... | 临床试验